Skip to main content
SpringerLink
Log in

Type I Endometrial Cancer: Advanced Stage

  • Chapter
  • First Online:
Case-Based Gynecological Oncology

  • 193 Accesses

Abstract

Advanced endometrial cancers account for 8–12% of the endometrial carcinoma, however the shows significantly less 5 year survival rate. Surgical resection remains mainstay of management of endometrial carcinoma, even in advanced stage. Moreover, the use of adjuvant radiotherapy and chemotherapy proven to have survival benefits at advanced stage. Therefore, multidisciplinary team lead multimodal therapy stays as the standard management of advanced endometrial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bray F, Loos AH, Oostindier M, Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer. 2005;117(1):123–31.

    Article  CAS  PubMed  Google Scholar 

  2. Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E, Martin-Hirsch P, Tsilidis KK, Kyrgiou M. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019;145(7):1719–30.

    Article  CAS  PubMed  Google Scholar 

  3. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491–505.

    Article  PubMed  Google Scholar 

  4. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93(6):468–74.

    PubMed  Google Scholar 

  5. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–97.

    Article  PubMed  Google Scholar 

  6. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017;10(10):CD007585.

    PubMed  Google Scholar 

  7. Aalders JG, et al. Endometrial cancer—revisiting the importance of pelvic and Para aortic lymph nodes. Gynecol Oncol. 2007;104(1):222–31.

    Article  PubMed  Google Scholar 

  8. Swift BE, Philp L, Atenafu EG, Malkani N, Gien LT, Bernardini MQ. Lymphadenectomy for high-grade endometrial cancer: does it impact lymph node recurrence? Eur J Surg Oncol. 2022;48(5):1181–7.

    Article  CAS  PubMed  Google Scholar 

  9. Demirkiran F. Controversies in the management of endometrial cancer 2012. Open J Obstet Gynecol. 2012;02(04):373–81.

    Article  Google Scholar 

  10. Joo WD, Schwartz PE, Rutherford TJ, Seong SJ, Ku J, Park H, et al. Microscopic omental metastasis in clinical stage I endometrial cancer: a meta-analysis. Ann Surg Oncol. 2015;22(11):3695–700.

    Article  PubMed  Google Scholar 

  11. Bayrak M, Yılmaz A, Yılmaz F, İlhan O, Oz Atalay F, Ozan H. Omental micrometastasis in endometrial cancer. Oncol Res Treat. 2019;42(9):466–9.

    Article  PubMed  Google Scholar 

  12. Turan T, Ureyen I, Karalök A, Taşçı T, Ilgın H, Keskin L, Kose MF, Tulunay G. What is the importance of omental metastasis in patients with endometrial cancer? J Turk Ger Gynecol Assoc. 2014;15(3):164–72.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Kaban A, Topuz S, Erdem B, Sozen H, Numanoğlu C, Salihoğlu Y. Is Omentectomy necessary for non-Endometrioid endometrial cancer. Gynecol Obstet Investig. 2018;83(5):482–6.

    Article  Google Scholar 

  14. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2–30.

    Article  PubMed  Google Scholar 

  15. Bruzzone M, Miglietta L, Franzone P, Gadducci A, Boccardo F. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. Gynecol Oncol. 2004;93(2):345–52.

    Article  CAS  PubMed  Google Scholar 

  16. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, Mychalczak BR, King ME. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2005;97(3):755–63.

    Article  PubMed  Google Scholar 

  17. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:36–44.

    Article  CAS  PubMed  Google Scholar 

  18. Rajkumar S, Nath R, Lane G, Mehra G, Begum S, Sayasneh A. Advanced stage (IIIC/IV) endometrial cancer: role of cytoreduction and determinants of survival. Eur J Obstet Gynecol Reprod Biol. 2019;234:26–31.

    Article  CAS  PubMed  Google Scholar 

  19. Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258–79.

    Article  PubMed  Google Scholar 

  21. Singh M, Zaino RJ, Filliaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;106:325–33.

    Article  CAS  PubMed  Google Scholar 

  22. Soumerai TE, Donoghue MTA, Bandlamudi C, et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res. 2018;24:5939–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, Moerman P, Vergote I, Amant F. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer. 2009;101(2):244–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118:14–8.

    Article  PubMed  Google Scholar 

  25. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–309.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.

    Article  CAS  PubMed  Google Scholar 

  27. Matei D, Filiaci VL, Randall M, et al. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma [abstract]. J Clin Oncol. 2017;35(15 suppl):5505.

    Article  Google Scholar 

  28. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:2159–66.

    Article  CAS  PubMed  Google Scholar 

  29. Aghajanian C, Fillaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018;150:274–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hogberg T, Signorelli M, de Oliveria CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer. 2010;46:2422–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pan Birmingham Gynecologic Oncology Centre, Birmingham, UK

    Sarada Kannangara

  2. National Cancer Institute, Maharagama, Sri Lanka

    Sarada Kannangara

  3. Teaching Hospital Mahamodara-Galle, Galle, Sri Lanka

    Sarada Kannangara

Authors
  1. Sarada Kannangara
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Birmingham City Hospital, Birmingham, UK

    Kavita Singh

  2. UCMS and GTB Hospital, New Delhi, India

    Bindiya Gupta

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kannangara, S. (2023). Type I Endometrial Cancer: Advanced Stage. In: Singh, K., Gupta, B. (eds) Case-Based Gynecological Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-36179-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-36179-1_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-36178-4

  • Online ISBN: 978-3-031-36179-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation